GeoVax Labs, Inc. announced that senior management will participate in investor and partner engagements during Biotech Showcase 2026 and the 44th Annual J.P. Morgan Healthcare Conference Week in San Francisco from January 12-15, 2026. The company will highlight its 2025 operational achievements, clinical pipeline progress, and strategic priorities for the coming year at these premier investor forums.
For business leaders and investors tracking biotechnology innovation, GeoVax's presentation will focus on several key programs with significant market implications. The company's CM04S1 COVID-19 vaccine program will be discussed, including clinical status, translational data, and regulatory pathways for high-risk and immunocompromised populations. This development addresses a critical unmet need in pandemic preparedness, as current authorized vaccines have shown limitations for vulnerable patient groups.
In oncology, GeoVax will present translational and clinical data supporting the development of Gedeptin® for head and neck cancer and other high-value solid tumor indications. The company's GEO-MVA program targeting Mpox and smallpox will also be featured, with discussions of regulatory progress, clinical strategy, and potential registration pathways supporting both civilian and biodefense applications. This dual-use approach positions the company at the intersection of public health and national security priorities.
Manufacturing advancements represent another area of strategic importance. GeoVax will highlight progress in continuous cell-line manufacturing technology that enables scalable, resilient, and domestic vaccine production. This capability has become increasingly valuable in the post-pandemic era as global supply chain vulnerabilities have prompted calls for more robust domestic manufacturing infrastructure.
Business development initiatives will also be addressed, with the company exploring partnership and collaboration opportunities to support pipeline advancement and long-term value creation. David Dodd, Chairman and CEO of GeoVax Labs, will present on January 13, 2026, at 2:30 pm PST at the Hilton Union Square in San Francisco. The presentation will be webcast live and may be accessed through the company's website.
The implications of GeoVax's progress extend across multiple sectors of the healthcare industry. For pharmaceutical companies and investors, the company's diverse pipeline represents potential opportunities in oncology, infectious diseases, and biodefense markets. The advancement of next-generation COVID-19 vaccines for immunocompromised patients addresses a significant market gap, while progress in solid tumor therapies could impact cancer treatment paradigms.
GeoVax's manufacturing platform developments have broader implications for vaccine production resilience and national security. As governments worldwide seek to strengthen domestic biomanufacturing capabilities, technologies enabling continuous, scalable production could become increasingly valuable. The company's regulatory progress with the GEO-MVA program also demonstrates how vaccine development can serve both public health and biodefense objectives simultaneously.
Management will host one-on-one investor and partner meetings throughout the conference to discuss GeoVax's progress across its pipeline. The company's participation in these high-profile investor conferences signals its maturation as a clinical-stage biotechnology firm with multiple programs approaching key inflection points in 2026.
